AML, Adult Clinical Trial
Official title:
Results From a Nationwide Cohort Temporary Utilization Authorization (ATU) of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC),Treated in France With Venetoclax Azacitidine
Following the results of the phase 1b and the phase 3 studies, Venetoclax/Azacitidine (VEN/AZA) was available in France for newly diagnosed AML patients ineligible-IC patients through the early access program the so-called ATU program. Venetoclax (VEN) has been available in France through the ATU since Feb 2021 and through the current post-ATU schema from the point of marketing authorization approval and up to the pending publication of reimbursement and price. Between February 15, 2021, and June 30, 2021, 285 requests for ATU were made to the pharmaceutical company (Abbvie) and led to the initiation of treatment of more than 230 patients. At the end of ATU period, all these 230 ATU patients continued to be treated by VEN/AZA as part of the current post-ATU period. Healthcare professionals and health care decision makers need real world data to better understand the benefit/risk profile of treatment. Early access to treatment in France is close to real-life setting condition.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04623944 -
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
|
Phase 1 | |
| Not yet recruiting |
NCT06313437 -
Revumenib in Combination With 7+3 + Midostaurin in AML
|
Phase 1 | |
| Terminated |
NCT04079738 -
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06052813 -
A Study of BN104 in the Treatment of Acute Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06027853 -
Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT02986620 -
Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia
|
||
| Recruiting |
NCT05601466 -
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT06066905 -
A Study of Chidamide With AZA in MRD Positive AML After Transplant
|
N/A | |
| Recruiting |
NCT05909501 -
Assessment of Geriatric Evaluations Impact on New AML Guidance
|
||
| Terminated |
NCT04614636 -
FT538 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06420063 -
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04128020 -
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
|
Phase 1 | |
| Active, not recruiting |
NCT04749355 -
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
|
Phase 2 | |
| Active, not recruiting |
NCT04755244 -
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
|
Phase 1/Phase 2 | |
| Completed |
NCT03194685 -
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03884829 -
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
|
Phase 1 | |
| Active, not recruiting |
NCT05177731 -
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
|
Phase 3 | |
| Not yet recruiting |
NCT06377579 -
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
|
||
| Recruiting |
NCT05025098 -
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
|
Phase 2 | |
| Not yet recruiting |
NCT06297772 -
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
|
Phase 3 |